Cecilia Götherström - Gynecology

Author Information

Cecilia Götherström is a distinguished researcher affiliated with the Department of Clinical Science, Intervention and Technology at the Division of Obstetrics and Gynecology, Karolinska Institutet, located at ANA Futura, floor 8, Alfred Nobels Allé 8, 141 52 Huddinge, Stockholm, Sweden. Her work primarily focuses on gynecology and related fields.

Research Contributions

Cecilia Götherström has made significant contributions to the field of gynecology and regenerative medicine. Her research spans several critical areas, including mesenchymal stem cell therapy for osteogenesis imperfecta, the effects of mesenchymal stromal cells derived from endometriotic lesions on natural killer cell function, and the safety considerations for in utero therapy clinical trials. Her studies often explore innovative therapies and their clinical implications, with a notable focus on the treatment of osteogenesis imperfecta and spinal cord injury repair.

Aliases

Cecilia Götherström is also known by the names C Götherström and C. Götherström.

Publication and Citation Metrics

Metric	Value
Citation Count	5950
H-index	25
Paper Count	68

Publications:

Mesencyhmal Stem Cell Therapy for Osteogenesis Imperfect.

DOI: 10.1097/GRF.0000000000000656

Year: 2021

The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function

DOI: 10.3389/fcell.2021.612714

Year: 2021

In Vitro Study of Human Immune Responses to Hyaluronic Acid Hydrogels, Recombinant Spidroins and Human Neural Progenitor Cells of Relevance to Spinal Cord Injury Repair

DOI: 10.3390/cells10071713

Year: 2021

Haemoglobin and red blood cell reference intervals during infancy

DOI: 10.1136/archdischild-2021-321672

Year: 2021

Living with Osteogenesis Imperfecta: A qualitative study exploring experiences and psychosocial impact from the perspective of patients, parents and professionals.

DOI: 10.1016/j.dhjo.2021.101168

Year: 2021

Trophic effects of multiple administration of mesenchymal stem cells in children with osteogenesis imperfecta

DOI: 10.1002/ctm2.385

Year: 2021

Soluble Transferrin Receptor during infancy and reference intervals for the Roche Cobas platform

DOI: 10.1111/ijlh.13391

Year: 2020

Fetal and maternal safety considerations for in utero therapy clinical trials: iFeTiS consensus statement.

DOI: 10.1016/j.ymthe.2020.10.012

Year: 2020

Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta

DOI: 10.1007/s11914-020-00594-3

Year: 2020

In Utero Stem Cell Transplantation

DOI: 10.1016/b978-0-7020-6956-7.00045-2

Year: 2020

What is Maternal Morbidity?

Who Can Visit a Gynecology Outpatient Clinic?

What is NICHD?

How to Prepare for Hormonal Profiling?

How Can Workflow Optimization Enhance Efficiency?

How is Recurrent Implantation Failure Diagnosed?

What are the consequences of delayed diagnosis?

How Do Birth Control Pills Affect Hormonal Shifts?

How Are Pelvic Floor Disorders Diagnosed?

How is Endometrial Atrophy Treated?

Partnered Content Networks

Relevant Topics